Need a Reliable Peptide Supplier? Click HERE!!!SponsoredVisit ↗
VIP Peptide and BAC Water Mix

VIP Peptide Reconstitution Calculator

Enter the amount you want to measure. The vial buttons will highlight which vial strengths create cleaner syringe-unit measurements.

What amount do you need?

Type the target amount, then choose mg or mcg. Example: 2mg or 500mcg.

Work the dose out from body weight

Syringe size:
Possible vial strengths:
Best Match Good Match Usable Harder to Measure

Example VIP Peptide Titration Schedule

ItemDetails
CIRS protocol50 mcg intranasal 4×/day
Inhaled (trial)300 mcg/day
Half-life~1–2 minutes
IV (trials)Hospital only

As-needed dosing suits acute flares only; the structured CIRS/MCAS protocols are scheduled (4×/day for weeks to months). Intravenous trials in ARDS failed the primary endpoint (survival signal only secondary). Hypotension is the main dose-limiting effect.

Possible vial strengths:

What Is It?

VIP Peptide

Vasoactive intestinal peptide.

Bacteriostatic Water

Sterile water containing a bacteriostatic preservative, commonly used when preparing multi-use research vials.

How To Mix VIP Peptide

1
Clean

Use alcohol swabs to clean the tops of both vials.

2
Draw BAC Water

Draw the selected amount of bacteriostatic water.

3
Inject Slowly

Add the liquid slowly down the side of the vial.

4
Swirl Gently

Do not shake. Swirl gently until dissolved.

5
Store Properly

Store as directed and protect from heat and light.

Best Practices & Common Mistakes

Best Practices

  • Use sterile technique.
  • Protect from light and heat.
  • Store refrigerated when appropriate.
  • Use clean syringe-unit math before measuring.

Common Mistakes

  • Confusing milligrams with milliliters.
  • Choosing an option with awkward decimal units.
  • Using too little liquid for very small measurements.
  • Shaking the vial aggressively.

VIP Peptide Storage & Handling

Lyophilized Powder: −20°C (−4°F) for long-term storage (up to 24 months). Refrigeration 2–8°C (36–46°F) for short-term use (up to ~3 months). Original sealed vial in the freezer is safest.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.

Frequently Asked Questions

VIP is a 28-amino-acid neuropeptide from the secretin/glucagon family, first isolated from the intestine in 1970 but found throughout the nerves, brain, lungs, and immune system. Despite the "intestinal" name, it acts body-wide as a vasodilator, a potent anti-inflammatory and immune modulator, and a circadian regulator, signaling through the VPAC1 and VPAC2 receptors. It's most commonly used as a compounded nasal spray, and also sold as a research peptide.
VIP's broadest interest is anti-inflammatory: it's studied in autoimmune and airway conditions, and its strongest conventional clinical evidence is a 2010 trial of inhaled VIP in sarcoidosis. It's also examined for pulmonary arterial hypertension, mast cell activation (MCAS), circadian and neuroprotective effects, and glucose regulation via VPAC2. Most of this is early or small-scale, so outside its diagnostic and investigational settings, these are potential uses rather than proven treatments.
VIP is best known in the alternative-medicine world as the final step of the Shoemaker protocol for CIRS (chronic inflammatory response syndrome) from water-damaged buildings, where it's used to correct inflammatory markers (like TGF-β1 and MMP-9) after upstream issues are addressed. This use is popular but sits outside mainstream medicine and rests on small studies from one research group. It differs from KPV, another anti-inflammatory peptide — VIP is a broad receptor-signaling neuropeptide, while KPV is a tiny tripeptide fragment.
VIP is most often used as a pre-made compounded nasal spray (commonly ~50 mcg per spray), which isn't reconstituted at home; only a research-grade lyophilized powder is mixed. For a 5 mg vial, adding 2 mL of bacteriostatic water gives 2.5 mg/mL, so a 100 mcg amount draws to 0.04 mL (4 units on a U-100 syringe) — very small, which is why nasal delivery is common. With a ~1–2 minute half-life there's no established injectable dose, so any figure is a research choice.
VIP is not FDA-approved for any indication — nasal and injectable forms are compounded or investigational (the injectable analog Aviptadil got Fast Track for COVID-ARDS but isn't approved) — so it's used off-label under a provider. Because it's a potent vasodilator, common effects include facial flushing, a transient drop in blood pressure, and nasal irritation, and it can add to blood-pressure-lowering drugs; loose stools can occur since VIP stimulates intestinal secretion. Storage: keep the powder or spray cold and protected from light, and use reconstituted or compounded solution within its dated window.
Practical takeaway: If your goal involves weight management, metabolic health, recovery, physical performance, cognitive function, appearance, or general well-being, discuss it with a licensed healthcare professional. They can help you evaluate approved, evidence-based options rather than relying on an unapproved or investigational compound. This calculator is intended only for transparent research-reference calculations and does not determine an appropriate amount, recommend use, or replace professional medical guidance.

About the author

Maria Hrabina is a pharmacist and scientific reviewer with a strong interest in peptide science, pharmacology, and emerging therapeutic compounds.

Her work focuses on understanding how peptide-based compounds interact with biological signaling pathways and how they are being investigated across areas such as metabolic health, dermatology, recovery, regenerative research, and pharmaceutical development.

Maria follows research on a broad range of peptides, from compounds used in approved medicines to experimental molecules still being evaluated in laboratory, preclinical, and clinical studies.

Her approach combines scientific curiosity with critical evaluation of evidence. She believes promising mechanisms and early research deserve attention, but should not be presented as established clinical benefits until they are supported by adequate human data.

Her areas of focus include scientific literature review, mechanisms of action, pharmacology, pharmacokinetics, safety, pharmaceutical formulation, and the overall quality of evidence behind peptide-based compounds.

She is particularly interested in the process of translating an experimental molecule into a reliable pharmaceutical product — including compound characterization, purity, stability, formulation, dose selection, safety assessment, and controlled clinical trials.

Maria believes peptide science has significant long-term potential, but that its progress depends on rigorous research, high manufacturing standards, transparent safety data, and responsible scientific communication.

Through her writing, she aims to help readers understand both sides of peptide research: what makes these compounds scientifically promising and what questions remain before their potential can be considered clinically established.

Areas of interest: Peptide Science · Therapeutic Peptides · Peptide Pharmacology · Metabolic Peptides · Cosmetic Peptides · Drug Development · Pharmacokinetics · Drug Safety · Pharmaceutical Formulation · Emerging Therapies · Evidence-Based Medicine

Important: This tool is for informational and research-reference purposes only. Not intended for human or veterinary use.
← All peptides